Health 2.0 announces keynotes and preliminary program

11 - 12 May 2016, Barcelona, Spain.
Health 2.0 announces keynote speakers and preliminary program for the 7th Annual Health 2.0 Europe Conference. After a highly successful conference last May in Barcelona, the International event series will be back for another 3 full days discussing challenges faced by the healthcare system and showcasing the latest technologies and innovations that are making an impact.

Health 2.0 Europe is a truly international conference, bringing speakers from all across the world to discuss and find solutions to those healthcare challenges from a global perspective. It will bring together 600 digital health champions including entrepreneurs, executives, thoughtleaders, investors, physicians, and patients over insightful keynotes, interactive workshops, animated round tables and more than 50 rapid fire live demo.

The keynote speakers already confirmed are:

  • Esther Dyson, active business angel and board member in various healthcare companies, she was named by Forbes as one of the most powerful American business woman. She will share her vision on the healthcare challenges and how to tackle them.
  • Dr. Rafael Grossmann, the surgeon who practiced the 1 st live surgery using Google Glass will showcase exclusive innovative solutions he is using and that are supporting both healthcare professionals and enhancing patients' experience.
  • Damien Marmion, Global Head of Health at AXA, will share AXA’s vision as an insurance pioneer in reimbursing digital health solutions and the role of reimbursement in accelerating adoption of digital health in Europe.
  • Dr. Julio Mayol, chief medical and innovation officer at San Carlos Hospital in Madrid, will give his vision on how hospitals should look at health 2.0 solutions and present their successful Smart Health Lab, an initiative launched to design, develop and implement innovative solutions.
  • Pēteris Zilgalvis, Head of Unit for eHealth and Well Being in DG CONNECT, will share the vision and strategic plan of the European Commission on getting a more dynamic digital health ecosystem, involving every stakeholder.

Health 2.0 Europe takes into account all the different stakeholders of the digital health ecosystem. Some of the topics that we will be discussing this year:

  • Solutions for hospitals and healthcare professionals
  • Building a new framework for Health 2.0 adoption in the clinic setting
  • Building Blocks to a Dynamic Health 2.0 Ecosystem in Europe
  • Health 2.0 Applications in Emerging Markets
  • Data Analytics: Structuring Information for DecisionMaking
  • Choosing your Digital Health Accelerator
  • Pharma 2.0: Going Beyond the Pill
  • Frontiers of Health 2.0: What's Next?
  • Power to the patient
  • Technology promoting behaviour change and healthy
  • Health 2.0 transforming the daily mission of nurses
  • Who will pay for Health 2.0? An investor's discussion
  • Reimbursement players, trends, criteria and processes
  • SHUSH topics and the famous unmentionables
  • From Health to WellBeing: the rise of wearables and consumer interfaces

For further information and to register, please visit:
https://goo.gl/IVCb3P

Early bird prices end on 18th March. Book you ticket now using the code EHNEWS16 to get 15% discount.

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]